NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
Clinical Trials
11 trialsNCT03423199 2024-03-22
PATHWAY
National Cancer Center, Japan
Phase 3 Active not recruiting
NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02866955 2020-03-09
EFESE
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT00684216 2017-09-14
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT00293540 2016-07-27
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
International Breast Cancer Research Foundation
Phase 3 Completed
NCT00365599 2014-11-21
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00241449 2012-06-06
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
AstraZeneca
Phase 3 Completed
NCT00541138 2011-09-21
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
City of Hope Medical Center
Phase 2 Completed
NCT00532454 2010-02-10
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
National Cancer Center, Korea
Phase 2 Terminated
NCT00001436 2008-03-04
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed